Unravelling the Role of Gut and Oral Microbiota in the Pediatric Population with Type 1 Diabetes Mellitus
- PMID: 39408940
- PMCID: PMC11477131
- DOI: 10.3390/ijms251910611
Unravelling the Role of Gut and Oral Microbiota in the Pediatric Population with Type 1 Diabetes Mellitus
Abstract
Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease that results in the destruction of pancreatic β cells, leading to hyperglycaemia and the need for lifelong insulin therapy. Although genetic predisposition and environmental factors are considered key contributors to T1DM, the exact causes of the disease remain partially unclear. Recent evidence has focused on the relationship between the gut, the oral cavity, immune regulation, and systemic inflammation. In individuals with T1DM, changes in the gut and oral microbial composition are commonly observed, indicating that dysbiosis may contribute to immune dysregulation. Gut dysbiosis can influence the immune system through increased intestinal permeability, altered production of short chain fatty acids (SCFAs), and interactions with the mucosal immune system, potentially triggering the autoimmune response. Similarly, oral dysbiosis may contribute to the development of systemic inflammation and thus influence the progression of T1DM. A comprehensive understanding of these relationships is essential for the identification of biomarkers for early diagnosis and monitoring, as well as for the development of therapies aimed at restoring microbial balance. This review presents a synthesis of current research on the connection between T1DM and microbiome dysbiosis, with a focus on the gut and oral microbiomes in pediatric populations. It explores potential mechanisms by which microbial dysbiosis contributes to the pathogenesis of T1DM and examines the potential of microbiome-based therapies, including probiotics, prebiotics, synbiotics, and faecal microbiota transplantation (FMT). This complex relationship highlights the need for longitudinal studies to monitor microbiome changes over time, investigate causal relationships between specific microbial species and T1DM, and develop personalised medicine approaches.
Keywords: FMT; SCFAs; T1DM; children; gut microbiome; oral microbiome; probiotics.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Targeting gut microbiota as a possible therapy for diabetes.Nutr Res. 2015 May;35(5):361-7. doi: 10.1016/j.nutres.2015.03.002. Epub 2015 Mar 14. Nutr Res. 2015. PMID: 25818484 Review.
-
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis.Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 9. doi: 10.1007/s00210-025-04069-z. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40202676 Review.
-
Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.Front Endocrinol (Lausanne). 2021 Apr 7;12:632335. doi: 10.3389/fendo.2021.632335. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897618 Free PMC article. Review.
-
Gut microbiota implication in diabetic kidney disease: mechanisms and novel therapeutic strategies.Ren Fail. 2025 Dec;47(1):2517402. doi: 10.1080/0886022X.2025.2517402. Epub 2025 Jun 25. Ren Fail. 2025. PMID: 40563141 Review.
-
Dysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapies.Int J Mol Sci. 2021 Mar 9;22(5):2763. doi: 10.3390/ijms22052763. Int J Mol Sci. 2021. PMID: 33803255 Free PMC article. Review.
Cited by
-
Current Data on the Role of Amino Acids in the Management of Obesity in Children and Adolescents.Int J Mol Sci. 2025 Jul 24;26(15):7129. doi: 10.3390/ijms26157129. Int J Mol Sci. 2025. PMID: 40806262 Free PMC article. Review.
References
-
- Gregory G.A., Robinson T.I.G., Linklater S.E., Wang F., Colagiuri S., de Beaufort C., Donaghue K.C., Harding J.L., Wander P.L., Zhang X., et al. Global Incidence, Prevalence, and Mortality of Type 1 Diabetes in 2021 with Projection to 2040: A Modelling Study. Lancet Diabetes Endocrinol. 2022;10:741–760. doi: 10.1016/S2213-8587(22)00218-2. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical